Therefore, this study investigates the role of TLR3 agonists in modulating the expression of PD-L1, an immune-related molecule present on the surface of lung adenocarcinoma cells, with the aim of enhancing the efficacy of sindelimab. This evidence concerns the gene TLR3 and lung adenocarcinoma.